I'm assuming this patent is directly related to the followning:
Patent claim #'s 10, 11, 12 and 18;
10. The method of claim 1, wherein the treatment-refractory cutaneous or subcutaneous cancerous tumor is a treatment-refractory, cutaneous or subcutaneous, breast cancer tumor or a treatment-refractory, cutaneous or subcutaneous, triple-negative breast cancer tumor.
11. The method of claim 1, wherein the cancerous tumor is melanoma.
12. A method of treating a subject having a treatment-refractory, cutaneous or subcutaneous, cancerous tumor comprising: a) administering a first treatment at a first time (T1), wherein the first treatment comprises injecting the cancerous tumor with a first effective dose of at least one plasmid encoding at least one immunostimulatory cytokine and administering a first electroporation therapy to the cancerous tumor, wherein the first electroporation therapy further comprises administration of at least one voltage pulse having a duration of about 100 microseconds to about 1 millisecond; b) administering a second treatment at a second time (T2) after T1, wherein the second treatment comprises injecting the cancerous tumor with a second effective dose of at least one plasmid encoding at least one immunostimulatory cytokine and administering a second electroporation therapy to the cancerous tumor, wherein the second electroporation therapy further comprises administration of at least one voltage pulse having a duration of about 100 microseconds to about 1 millisecond; c) administering a third treatment at a third time (T3) after T2, wherein the third treatment comprises injecting the cancerous tumor with a third effective dose of at least one plasmid encoding at least one immunostimulatory cytokine and administering a third electroporation therapy to the cancerous tumor, wherein the third electroporation therapy further comprises administration of at least one voltage pulse having a duration of about 100 microseconds to about 1 millisecond; and d) administering a fourth treatment at a fourth time (T4) after T3, wherein the fourth treatment comprises administering an effective dose of an immune checkpoint inhibitor to the subject.
OncoSec Announces Collaboration For TAVO™ In Australia With Emerge Health--TAVO to Become Revenue Generating Potentially As Early As Year-End 2019
Collaboration uses Australia's Special Access Scheme (SAS) Allowing Patients Prescription Access To TAVO at Commercial Rates Prior To Regulatory Approval
SAN DIEGO and PENNINGTON, N.J., May 29, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, and Emerge Health Pty (Emerge), the leading Australian company providing full registration, reimbursement, sales, marketing and distribution services of therapeutic products in Australia and New Zealand, have entered into a collaboration agreement commercializing OncoSec's proprietary TAVO (enhanced IL-12 DNA-plasmid) and making it available under Australia's Special Access Scheme (SAS) in 2019. As a specialized Australian pharmaceutical company focused on the marketing and sales of high quality medicines to the hospital sector, Emerge has previously made numerous other products successfully available under Australia's SAS.
This collaboration will allow OncoSec to begin generating revenue, potentially as early as the fourth quarter of 2019. The ability to begin this process in Australia with TAVO sets OncoSec apart from other clinical-stage companies developing therapies for the treatment of refractory metastatic melanoma. TAVO will be the only drug available under the SAS program for melanoma patients who have failed checkpoint inhibitor or targeted therapy.
The SAS was introduced by Australia's Therapeutics Goods Administrations (TGA) in recognition that there are circumstances where patients need access to therapeutic products that are not on the Australian Register of Therapeutic Goods (ARTG). Australia's SAS allows physicians to prescribe and treat patients with drugs not yet approved in Australia provided those patients have a condition from which death is reasonably likely to occur within a matter of months, or from which premature death is reasonably likely to occur in the absence of early treatment. 1
In 2019, it is estimated that 15,229 new cases of melanoma skin cancer will be diagnosed in Australia (8,899 males and 6,330 females) and that it will become the ninth most common cause of death from cancer in 2019. TAVO, to be used for melanoma patients who have failed either checkpoint inhibitors or targeted therapy, could treat up to 1,000 Australian patients.
I wonder since the patent is for all trial indications--if that may help extend Australia's SAS program to Triple-negative breast cancer and Head and Neck cancer on top of their present approval for melanoma.
